This Article Full Text (PDF) Other Versions of this Article: AAC.01256-06v1 51/3/1109    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smith, A. T. Articles by Sullivan, W. J. Search for Related Content PubMed PubMed Citation Articles by Smith, A. T. Articles by Sullivan, W. J., Jr.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01256-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii

Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartmento di Studi Farmaceutici, Universita degli Studi di Roma "La Sapienza", P.le A. Moro 5, I-00185 Roma, Italy, Istituto di Biologia e Patologia Molecolari CNR, Dip. Genetica e Biologia Molecolare, Universita degli Studi di Roma "La Sapienza", P.le A. Moro 5, I-00185 Roma, Italy

^* To whom correspondence should be addressed. Email: wjsulliv{at}iupui.edu.

	Abstract

We report that quinoline derivative MC1626, first described as an inhibitor of the histone acetyltransferase (HAT) GCN5, is active against the protozoan parasite Toxoplasma gondii in vitro. However, MC1626 does not inhibit Toxoplasma GCN5 HATs, nor reduce HAT-mediated activity; rather, this quinoline may target the plastid organelle called the apicoplast.